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Abstract
Objective: Depression is a frequent, recurrent and chronic condition with high levels of functional disability. The Brazilian Medical 
Association Guidelines project proposed guidelines for diagnosis and treatment of the most common medical disorders. The objective 
of this paper is to present a review of the Guidelines Published in 2003 incorporating new evidence and recommendations. Method:
This review was based on guidelines developed in other countries and systematic reviews, randomized clinical trials and when absent, 
observational studies and recommendations from experts. The Brazilian Medical Association proposed this methodology for the whole 
project. The review was developed from new international guidelines published since 2003. Results: The following aspects are presented: 
prevalence, demographics, disability, diagnostics and sub-diagnosis, efficacy of pharmacological and psychotherapeutic treatment, 
costs and side-effects of different classes of available drugs in Brazil. Strategies for different phases of treatment are also discussed. 
Conclusion: The Guidelines are an important tool for clinical decisions and a reference for orientation based on the available evidence 
in the literature.
Descriptors: Depression; Review; Diagnosis; Treatment outcome; Sociology, medical
Resumo
Objetivo: A depressão é uma condição freqüente, em geral recorrente e de curso crônico, associada com níveis altos de incapacitação 
funcional. A Associação Médica Brasileira, por meio do projeto “Diretrizes”, buscou desenvolver guias para diagnóstico e tratamento das 
doenças mais comuns. O objetivo deste trabalho é o de atualizar as Diretrizes desenvolvidas em 2003, incorporando novas evidências 
e recomendações. Método: A metodologia utilizada foi a proposta pela Associação Médica Brasileira para o projeto Diretrizes. Assim, o 
trabalho foi baseado em diretrizes desenvolvidas em outros países aliadas a artigos de revisão sistemáticos, ensaios clínicos randomiza-
dos e, na ausência destes, estudos observacionais e recomendações de grupo de experts. A atualização foi realizada a partir de novas 
diretrizes internacionais publicadas a partir de 2003. Resultados: São apresentados dados referentes a prevalência, demografia, inca-
pacitação, diagnóstico e subdiagnóstico de depressão. Em relação ao tratamento, são mostrados dados sobre a eficácia do tratamento 
medicamentoso e psicoterápico das depressões, além do perfil de custos e de efeitos colaterais das diferentes classes de medicamentos 
disponíveis no Brasil, além do planejamento das diferentes fases do tratamento. Conclusão: As diretrizes têm como objetivo servir de 
orientação para a tomada de decisões clínicas baseada nas evidências científicas da literatura disponível.
Descritores: Depressão; Revisão; Diagnóstico; Resultado de tratamento; Sociologia médica
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Introduction
Depression is a relatively common condition,1 with a chronic2
and recurrent course.3-5 It is frequently associated with functional 
impairment6 and the compromising of the physical health.7-9
Depressed patients show limitation in their activity and well-
being,10,11 besides a higher utilization of health services.12
However, depression is still under-diagnosed and under-treated. 
Between 30 and 60% of depression cases are not detected by the 
general clinician in primary care units.13,14 Many times, depressed 
patients also do not receive sufficiently adequate and specific 
treatment.15 The morbimortality associated with depression can be, 
in a good proportion, prevented (in nearly 70%) with the correct 
treatment.16
In the year 2001, the Brazilian Medical Association (AMB) 
developed the Guidelines Project, aimed at establishing guidelines 
for the identification and treatment of  a series of common medical 
conditions, among them depression. In 2003, the Revista Brasileira 
de Psiquiatria (RBP) published a more detailed version of these 
guidelines.17 Recently, following an initiative of the AMB, these 
guidelines were reviewed and the RBP asked the authors to publish 
a new more detailed version of this review on depression.
Therefore, the main objective of this article was to review 
and update the Guidelines for Depression published in 2003, 
emphasizing the diagnosis and treatment of unipolar depression. 
The original objectives of the guidelines are the same, namely: 1) to 
provide subsidies to enhance the capability of diagnosing new cases 
of depression; 2) to provide a rational approach for the treatment 
of depression, defining which cases should be treated, how to treat 
them, and when to refer them to the psychiatrist/specialist;3) to 
raise the professionals’ conscience about the importance of their 
role in reducing the impact of morbidity-mortality and improving 
the depressed patients’ quality of life.
Method
The original guidelines of 2003 were based on four documents 
developed by renowned institutions or groups: British Association 
for Psychopharmacology,18 American Psychiatric Association,19
Department of Health and Human Resources of the United States 
(Depression Guideline Panel)20,21 and the Committee for the 
Prevention and Treatment of Depression of the World Psychiatric 
Association.22 The criterion to select these documents was having 
used mainly systematic review articles, randomized clinical trials 
and in their absence, observational studies and recommendation 
of an expert group. Most data used in these studies were of 
depressed patients who sought psychiatric services, due to the 
small (although rising) number of studies based on patients of 
primary care service.  
For this review we made a search in Pubmed using the keyword 
“unipolar depression”. The search was limited by the type of article 
(practice guidelines), language (English) and year (from 2002 
onward). With this search we found 23 publications. Their abstracts 
were examined, being selected five which met the criteria of the 
guidelines for the diagnosis and treatment of unipolar depression 
in adults.23-27
The main complimentary and innovative elements of these 
documents were added to the Guideline published in 2003.
Part 1 - Depression: prevalence and diagnosis
Depression is a frequent problem
Prevalence studies in Western countries show that depression is a 
frequent disorder. The annual prevalence in the general population 
varies from 3 to 11%.28-30 One meta-analysis of 23 studies of 
prevalence and incidence of depression, using the sample pool, 
found a prevalence of 4.1% in one year and 6.7% in lifetime.1 These 
data contrast with the main American study on the subject, which 
found respectively 6.6% (one year) and 16.2% (in lifetime).3
 Studies developed with clinical samples (of patients) show a 
higher prevalence. In patients of primary care health services, 
Ustun e Sartorius,31 in an international study accomplished in 14 
countries, showed a prevalence median above 10%. In specific 
populations, such as of patients with recent stroke, it reaches 33%,32
achieving 47% in cancer patients.33 In hospitalized patients due 
to any physical disease, the prevalence of depression ranges from 
22% to 33%.22
Depression is more frequent among women
The prevalence of depression is two to three times more frequent 
in women than in men, even considering studies accomplished in 
different countries, communities or patients who seek psychiatric 
services.34
Depression is a chronic and recurrent disorder
Nearly 80% of the individuals who received a treatment for a 
depressive episode will have a second episode in their lifetime, 
being the median of four in lifetime.18 The mean duration of an 
episode ranges from 16 to 20 weeks and 12% of the patients have 
a chronic course without symptom remission.35,36
Depression is an incapacitating disorder
Using a global scale to compare several diseases, the estimations 
are that depression was the fourth specific cause of incapacitation 
in the 1990’s. The forecast for the year 2020 is that it will be the 
second cause in developed countries and the first in developing 
countries.37 When compared to the main chronic medical conditions, 
depression is only equivalent, in terms of incapacitation, to severe 
cardiac ischemic diseases,6 causing more impairment in the health 
status than angina, arthritis, asthma and diabetes.38
Depression is scarcely diagnosed by non-psychiatric 
physicians
In primary care services and other general medical services, 30 
to 50% of depression cases are not diagnosed.13,14,39
The reasons for this under-diagnosis stem from factors 
related to patients and physicians. Patients may have prejudice 
regarding the diagnosis of depression and disbelief in relation 
to the treatment. The factors related to physicians include lack 
of training, lack of time, disbelief regarding the effectiveness 
of the treatment, recognition only of the physical symptoms of 
depression and identification of the symptoms of depression as 
an “understandable” reaction”.40,41
The training of non psychiatric physicians to diagnose depression, 
as well as the use of screening instruments for depression have 
not shown neither a substantial nor an enduring impact on the 
appropriate management of depression cases.42,43 The detection of 
depression by the non psychiatric physician does not seem to be 
associated with the adequate indication of treatment.44
There are simple questions which help to improve the detection 
of depression by the physician
The modern classificatory systems in psychiatry operationalized 
the diagnosis of depression, facilitating its recognition and the 
scientific communication between professionals (Table 1).  
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In Table 2, we present some questions that can improve the 
detection of depression cases by non psychiatric physicians.
Besides the diagnosis of the depressive episode, there are other 
presentations of depression with less intense symptoms, although 
with a similar incapacitating degree, which are very frequent in 
primary care services
Dysthymia is a chronic depressive disorder with lower intensity of 
symptoms, which is present for at least two years with occasional 
and short periods of well-being. Besides the depressed mood, 
there should be present up to three of the following symptoms: 
low energy, insomnia, low self-esteem, poor concentration, crying, 
decreased sexual drive as well as of other pleasant activities, 
feeling of hopelessness and distress, difficulty of dealing with 
daily responsibilities, pessimism in relation to the future, social 
withdrawal, and slowed speech.45 Evidence of other naturalistic 
studies shows that the impairment of the social and occupational 
functioning in dysthymia is higher than that of depressive 
episodes,6,48-51 suggesting that the extension of the social and 
occupational impairment be more related to the duration of 
symptoms than to their intensity.
Mixed anxiety and depression disorder includes patients with 
anxiety and depression symptoms and none of the set of symptoms 
considered separately is sufficiently intense to justify a diagnosis. In 
this disorder, some autonomic symptoms (trembling, palpitation, dry 
mouth, stomach pain) may be present, even though intermitently.45
Its prevalence is 4.1% in primary health services treating this 
disorder.52,53
Recently, a particular attention has been given to mildly depressed 
patients who do no meet the diagnostic criteria (subsyndromic 
depression), but who have high risk of presenting with future 
depressive episodes.22
Before starting an antidepressant treatment it is important to 
exclude a diagnosis of bipolar disorder 
Nearly 10 to 20% of unipolar depressed patients have their 
diagnosis changed to bipolar mood disorder along time.54,55 It is 
highly clinically relevant to know that antidepressants may trigger 
mania in patients with apparent unipolar disorder.56
Part 2: Treatment
1. General considerations
Antidepressants are effective in the acute treatment of moderate 
and severe depressions, however, they do not differ from placebo 
in mild depressions
There is striking evidence in the literature that antidepressants are 
efficient in the treatment of moderate to severe acute depression, 
either improving the symptoms (response) or eliminating them (full 
remission).18
The response rate in intention-to-treat samples range from 50 to 
65%, against 25 to 30% shown by placebo in randomized clinical 
studies.21,57,58 A systematic review of antidepressant treatment 
in depressive disorder associated with physical disease showed 
similar response rates.57,59 Other review of meta-analysis studies of 
depressed patients treated in primary care services showed response 
rates between 50 and 60%, which are similar to those obtained in 
samples of psychiatric patients.57
Antidepressants did not show advantages in relation to placebo in 
mild depressions, as a good response is observed in both.60-62
In patients with psychotic depression, the association 
of antidepressants with antipsychotics is more effective 
antidepressants alone
There is consistent literature showing that antidepressants or 
antipsychotics used alone have worse result than when combinedly 
used.63,64 Both typical and atypical antipsychotics are effective, 
and there are no controlled data that compare “new” versus “old” 
antipsychotics.25
The full remission of symptoms should be the goal of any 
antidepressant treatment
There is consistent evidence in the literature that the permanence 
of residual depression symptoms are associated with  worse quality 
of life, worse functionality, higher suicide risk, higher relapse rate 
and increased consumption of health services.65,66
Antidepressants are effective in the acute treatment of dystymia
One meta-analysis of 15 randomized clinical trials for the 
treatment of dystymia showed that 55% of the patients respond to 
antidepressants, compared to 30% with placebo.67
Specific psychological treatments for depressive episode are 
effective with higher  evidence for mild to moderate depressions
Recent pieces of evidence established by review studies and 
meta-analysis have shown efficacy in the acute treatment of 
depressions for the following forms of psychological treatments: 
cognitive-behavioral psychotherapy,68 behavioral psychotherapy,69
interpersonal psychotherapy70 and problem solving psychotherapy.71
Other psychotherapies have also shown efficacy, although supported 
by a lower number of studies: brief psychodynamic psychotherapy,72
marital therapy73 and counselling.74
Evidence suggests 1) a similar efficacy for antidepressants, 
cognitive-behavioral behavioral and interpersonal psychotherapy or 
combined treatments in mild to moderate depressions; 2) a higher 
efficacy of combined treatments (antidepressants + psychotherapy) 
in moderate to severe depressions; and 3) an absence of evidence 
for very severe depressions.24
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Different antidepressants have similar efficacy for the majority of 
depressed patients, varying in relation to the profile of side effects 
and the potential interaction with other medications 
Systematic review and meta-analyses studies suggest that 
commonly available antidepressants have a comparable efficacy 
for the majority of patients seen in primary care or in outpatient 
services.75-77
The meta-analyses about side-effects in the acute use of 
antidepressants have been concentrated in the comparison 
between selective serotonin reuptake inhibitors (SSRIs) and tricyclic 
antidepressants. The use of SSRIs is associated with a lower rate of 
treatment dropout as compared to tricyclic antidepressants, but the 
absolute difference is of only 3 to 5%.18,78 However, this difference, 
may increase with the duration of treatment18 and may be higher 
in the daily clinical practice.79
SSRIs antidepressants have more chance than tricyclic 
antidepressants to be prescribed in doses recommended for the 
recommended time.
There is consistent evidence that tricyclic antidepressants are 
prescribed in lower doses and for a shorter time than what is 
recommended.80-84 Nevertheless, there is no direct evidence that 
patients who received SSRIs have a better result than those who 
received tricyclic antidepressants.85
New antidepressants are more expensive than older drugs, but 
it remains controversial if the general cost of treatment would be 
higher. There are no Brazilian data about costs.
The price of medications is one of the aspects of the treatment 
cost. Factors such as the number of consultations, examinations 
requested, work absences, relapses and hospitalization days 
are some of the other data to be taken into consideration. Some 
studies have shown that the general costs of treatment with 
SSRIs and tricyclic antidepressants are close.86 However, most of 
pharmaeconomic studies have problems when it comes to outlying 
and/or conflict of interest, and their external validity is limited, as 
they refer to costs or routines which are specific to some centers or 
coutries.18 There are no Brazilian data in relation to this subject. 
The prescription of antidepressants is associated with the decrease 
of the risk of suicide.
Epidemiological studies in the last decades have revealed a 
decrease in the frequency of suicide with the prescription of 
antidepressants. Some data suggest that the treatment with SSRIs 
could increase the risk of suicide in some patients.87 Such risk would 
be increased in the beginning of the treatment.88 Comparatively, the 
risk of suicide is higher before starting the antidepressant treatment 
(prior month), being much lower in the first week of treatment, 
decreasing even more in the following weeks.89
2. Practical considerations
Weekly consultations in the beginning of the treatment are 
associated with higher adherence and better results in the short-
term
Naturalistic studies that compared the usual routines of the 
services with weekly interviews in the first four to six weeks showed 
a better outcome and higher adherence of patients who followed 
the weekly regime.57,90
The need of monitoring the response, side-effects, treatment 
adherence and risk of suicide also reinforce the weekly frequency 
as the advisable one in the initial phase of the treatment.18
The response to acute treatment with antidepressants is observed 
within two to four weeks after the beginning of use; however, the 
beginning of response uses to occur in the fist week.
The clinically significant response to antidepressants is not 
immediate and uses to occur between the second and the fourth 
week of utilization.18 However, the beginning of action seems to 
occur already in the first week. One meta-analysis of 46 studies 
showed that 35% of the improvement measured in assessment 
scales occur in the first week.91 Improvement within the first two 
weeks of treatment is associated with higher chances of responding 
to treatment.92,93 Absence of response within four weeks decreases 
the chance of subsequent response with the same treatment, 
although some patients could respond within six weeks.94,95
When a patient does not respond to the treatment the 
recommendation is to revise the factors related to non response:
1) correct diagnosis, assessing the possibility of a concurrent 
medical or psychiatric disease;18
2) adherence to treatment. The adherence to antidepressant 
treatment is relatively low, varying from 40 to 90% in different 
studies, being the mean equal to 65%;96
3) long duration of the disease;97-100
4) chronic social difficulties and persistent life events;14,101,102
5) severe episode or with psychotic symptoms;5,103-108
6) dystymia and severe personality disorder.109-114
The strategies used when a patient does not respond to the 
treatment with antidepressant medication consists of 1) increase 
of dose; 2) potentiation with lithium or triiodotironine (T3); 3) 
association of antidepressants; 4) change of antidepressant; 
5) electroconvulsive therapy (ECT); and 6) association with 
psychotherapy
There is limited evidence about which strategy would be the 
best alternative in cases of non response to a treatment initially 
proposed.115 One randomized study showed that the increase of 
fluoxetine up to 60mg in patients who had not responded to 20mg 
for eight weeks was more effective than potentiation with lithium 
or desipramine.116
Increase of the dose, when there is no response, seems to be 
a logical step, considering that there is a great individual variety 
in the plasma concentration of antidepressants and that there is 
uncertainty about which would an appropriate dose for a certain 
individual.18
There are no randomized studies comparing the continuation of 
an original treatment to the change for a different antidepressant. 
Controlled studies have methodological problems such as particular 
types of patients and small samples.18 Open studies show that nearly 
20 to 60% of patients respond to the change of antidepressants21
or to the change between SSRIs.117
One meta-analysis of four randomized clinical trials demonstrated 
that the potentiation of antidepressants with lithium carbonate in 
treatment-resistant patients showed that nearly 40% responded as 
compared to 10% with placebo.118
One meta-analysis also with four randomized clinical trials 
assessing the effect of the potentiation with triiodotironine showed 
a moderate size effect (0,6) regarding the improvement in the 
depressive symptomatology when compared to placebo, but the 
difference was non significant in relation to the rate of response 
(8%).119
As for ECT, open studies show response rates of 50% in treatment-
resistant depressed patients.120
There is some evidence that the association of antidepressant 
medication with cognitive-behavioral psychotherapy (CBT) or with 
interpersonal psychotherapy may improve the outcome of treatment-
resistant patients who seek psychiatric services.121,122 After an 
unsatisfactory response to antidepressants (SSRIs), patients assigned 
to receive different antidepressant strategies had outcomes similar to 
those who received CBT, being CBT better tolerated than the change by 
an antidepressant medication.123 The potentiation of the antidepressant 
effect with CBT has started its effect later than antidepressants.123
The chance that a following antidepressant treatment be 
successful decreases at each failed attempt
The number of previous attempts with antidepressant medication 
is a predictive factor for the treatment’s failure. Next step studies are, 
generally, problematic, for having small “n”, being non replicated 
and having very heterogeneous populations, what make difficult 
generalizations.24 One recent exception is the STAR*D project 
(Sequenced Treatment Alternatives for the Relief of Depression), 
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which involved nearly 4,000 patients followed-up along four stages 
in order to assess the performance of consecutive attempts with 
diverse antidepressant schemes.124 One of the main findings of 
the STAR*D project was precisely that the response to treatment 
decreased from 49% to 19% and the remission decreased from 
37% to 13% along the four study’s stages.125 Other recent 
studies corroborate the importance of absence of response to an 
antidepressant as a good predictive factor of unsatisfactory response 
to subsequent treatments.36
ECT is an acute treatment for depressions, being more efficient 
than antidepressant medications
Most studies with ECT involve severe and treatment-resistant 
patients. Meta-analyses show that ECT has a superior efficacy when 
compared to antidepressant medications.126-128 There is evidence that, 
when ECT is used as a 4th stage in a sequential study of antidepressant 
treatments, 82% obtained a clinically significant response.129
Transcranial magnetic stimulation and vagal nerve stimulation 
(VNS) are new options for the treatment of depression; however, 
the evidence that supports their use is still preliminary
Transcranial magnetic stimulation consists of the stimulation of the 
cerebral cortex, by means of a magnetic field. Meta-analyses found 
significant clinical effects.130,131 Nevertheless, the studies involved 
small samples, with a heterogeneous methodology, mostly studies 
exclusively on the acute phase, and few studies involve middle- and 
long-term follow-up.
VNS as an antidepressant treatment is based on its anatomical 
peculiarities, as it is projected to brain areas which are relevant for 
the generation and control of emotions.132 VNS has not shown to 
be more efficient than a control group with simulated treatment,133
although other studies with different doses have shown efficacy.134
Despite being approved by the Food and Drugs Administration (FDA) 
as an adjunct treatment for resistant depression, up to the moment 
it is questionable if VNS exerts a higher effect than placebo or other 
treatments and more controlled studies are urgently needed.135   
The planning of an antidepressant treatment involves the acute, 
the continuation and maintenance phases, each with specific 
objectives
The predominant model in the literature for the planning of 
antidepressant treatment involves the acute, continuation and 
maintenance phases.136
1) Acute phase. The acute phase includes two to three first 
months and has the objective of decreasing the depressive 
symptoms (response) or ideally the full attenuation with the return 
to the pre-morbid functioning level (remission).
2) Continuation phase. It corresponds to the four to six 
months which follow the acute treatment and aims to sustain 
the improvement obtained, preventing relapses within the same 
depressive episode. At the end of the continuation phase, patients 
who maintain the initial improvement are considered as recovered
from the index episode.
3) Maintenance phase. The objective of the maintenance phase 
is to prevent the occurrence of new episodes (recurrence). The 
maintenance phase, therefore, is recommended for those patients 
who have probability of recurrence.
One third of the patients with depressive episode with initial 
remission relapse in the first year 
The relapse rates decrease along time. They are estimated at 
20 to 24% in the first two months, 28 to 44% at four months, 
27 to 50% at six months and 37 to 54% at 12 months137. Similar 
results were described for depressed patients in general medicine 
outpatient settings with relapse of 37% within one year.138
Continuation antidepressant treatment for six months reduces 
the relapse risk in 50%
One meta-analysis of studies with patients in depressive episode 
treated with antidepressant for two to six months, besides remission, 
shows a relative risk of 0.5 when compared to placebo.139
The benefit of a treatment for more than six months after 
remission was demonstrated only for groups with history of recurrent 
depressive episodes.18
There are factors which seem to be associated with a higher risk 
of relapses/recurrences  
The following factors seem to be associated with a higher risk of 
relapse/recurrence: 1) number of previous episodes;140 2) residual 
symptoms;141 3) severity of depressive symptoms;142 4) longer 
duration of the episode;143,144 5) psychosis;145 6) level of treatment 
resistance;125 7) female gender;144,146 8) social stress/small social 
adjustment;141,147 and 9)life events.148
The effective dose of continuation treatment is the same of acute 
treatment
There are no controlled studies that define which is the best dose 
for a continuation treatment. Naturalistic studies show a benefit 
in continuing with the same dose of that of acute treatment when 
compared to reducing the dose.149
Maintenance treatment reduces the recurrence rate in patients 
with three or more episodes in the last five years
Controlled studies with patients with recurrent depressive episodes 
(typically three in the last five years) showed that the maintenance 
of an antidepressant medication prevents the recurrence in the 
following one to five years.78 The follow-up of patients with prior 
recurrent episodes demonstrated that only 20% of the patients who 
had received antidepressants showed recurrence as compared to 
80% of those who received placebo.150
One five-year naturalistic study showed a benefit of the sustained 
use of antidepressant beyond 28 weeks for patients who had had five 
or more prior episodes, but not for patients with less episodes.149
The effective dose for maintenance treatment is the same of 
acute treatment
Two controlled studies showed a higher recurrence rate in patients 
whose maintenance treatment was accomplished with half of the 
dose of acute treatment within the following two to three years,150,151
suggesting that the effective dose in the acute phase should be 
maintained in the long-term as to prevent recurrences.
Lithium seems to be an alternative to the antidepressants in 
maintenance treatment of depressive episodes, with reduction in 
the risk of suicide
Two meta-analyses showed the superiority of lithium when 
compared to placebo in the maintenance treatment of depressive 
episodes,152,153 and in one of them this difference was not 
statistically significant.153 There was no difference on antidepressant 
medications in the prevention of relapses and recurrences in 
patients with unipolar depression in the period of five months to 
three years.152,154
One meta-analysis showed that lithium had a reduction of 85% 
in the suicide rate as compared to a group of patients who used 
antidepressants.155
The abrupt suspension of antidepressant medications is associated 
with the appearance of discontinuation symptoms
Controlled studies with SSRIs and venlafaxine and open studies and 
case reports with tricyclic antidepressants and MAO inhibitors show 
that the abrupt suspension of the antidepressant treatment can lead to 
discontinuation symptoms which occur from the first days up to three 
weeks.156-159 Antidepressants have low potential for abuse160 and there 
is no evidence that discontinuation reactions are part of a syndrome of 
antidepressant addiction.161
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APPENDIX
RECOMMENDATIONS18
I- REFERRAL TO/COUNSELING WITH PSYCHIATRIST BT THE 
NON SPECIALIST PHYSICIAN
The referral to the psychiatrist is indicated in the following 
situations:
1) risk of suicide;
2) psychotic symptoms;
3) history of bipolar affective disorder.
The referral to, or counseling with, a psychiatrist is appropriate 
in the following situations: 
1) the physician feels incapable of dealing with the case;
2) two or more attempts of antidepressant treatment which failed 
or had partial response.
II- INDICATIONS OF ANTIDEPRESSANT TREATMENT
Moderate to severe depressive episodes and dystymia
The antidepressants medications are the first line of treatment 
independently from the presence of environmental factors.
Mild depressive episodes (first episode) 
1) Antidepressants are not indicated;
2) education, support and simple solution of problems are 
recommended;
3) monitoring for the persistence or for the development of 
moderate to severe depressive episodes.
Mild to persistent depressive episodes 
Therapeutic test with antidepressant medication.
Mild depressive episode in patient with previous history of 
moderate to severe depressive episode 
Consider treatment with antidepressant.
Mild to moderate depressive episodes 
Specific psychotherapies for depression (cognitive and interpersonal) 
are effective alternatives to the medications, depending on the 
availability of professionals and the patient’s preference.
III- CHOICE OF THE ANTIDEPRESSANT MEDICATION
1) Individualize the treatment considering the patient’s specific 
aspects;
2) in the absence of special factors, choose antidepressants that 
are well tolerated , safe when excessively taken and more likely to 
be taken in the prescribed doses. There is strong evidence regarding 
these criteria for SSRIs. However, mirtazapine, reboxetine and 
venlafaxine are also safe and well tolerated;
3) for severe depressive episodes in hospitalized patients, consider 
the use of tricyclic antidepressants or venlafaxine preferentially;
4) take into account also the following factors: a) prior response to 
a particular medication; b) tolerability and adverse effects in relation 
to a prior medication; c) side-effects profile  (for example, weight 
gain, sedation, alterations in the sexuality); d) low lethality in case of 
present or past suicide risk ; e) concomitant physical disease that may 
hamper the use of an specific antidepressant; f) use of concomitant 
medications that might interact with the antidepressant medication; 
g) concomitant psychiatric disease that might respond to a specific 
antidepressant (for instance, obsessive-compulsive disorder and 
SSRI); h) the patient’s preference; i) cost.
IV- THE MANAGEMENT OF AN ACUTE SITUATION
1) Reconsultations at each one or two weeks at the beginning of 
the treatment. Telephonic contacts by non medical trained health 
professionals can replace adequately some medical consultations;
2) at each revision, assess the response, adherence to treatment, 
collateral effects and risk of suicide;
3) educate the patient regarding the nature of the depressive 
disorder, of the side effects, of the benefits of the medication;
4) limit the dose of antidepressant provided considering the risk 
of suicide;
5) when prescribing a tricyclic or other antidepressant that need 
the progressive increase of the dose, increase the dose at each three 
to seven days as to allow the adjustment of side effects. 
V- MANAGEMENT OF THE ABSENCE OF RESPONSE TO THE 
TREATMENT INITIALLY PROPOSED
1) Treat the depressive episode for at least four weeks before 
considering changing the strategy.
2) If there is absence of response within four weeks: a) check 
the dose and the adherence to the treatment; b) revise the 
diagnosis, including the possibility of the presence of psychiatric 
comorbidity or physical disease, that should thus receive 
treatment; c) consider the presence of social factors that should 
be dealt with if present.
3) If there is partial response within four weeks: a) continue the 
treatment for two weeks more.
4) If there is absence of response within four weeks (after 
verification of item 2) or partial response after six weeks:
a) increase the dose; 
b) replace the dose by another class of a replace the dose with 
another class of antidepressants; 
c) consider changing for MAOI in patients with atypical symptoms 
(weight gain, hypersomnia, hyper-sensitivity to criticism, reactive 
mood to external events).
5) Absence of response to a second antidepressant: 
a) add a potentiating agent;
b) add psychotherapy; 
c) electroconvulsive therapy.
NOTE: The use of potentiating agents, the prescription of MAOI 
and electroconvulsive therapy should be accomplished with 
psychiatric assistance or by a psychiatric service.
VI- CONTINUATION TREATMENT
1) Continue the antidepressant treatment for at least six months 
after the remission of the symptoms of the depressive episode;
2) in patients who persist with residual symptoms, maintain the 
treatment for a more prolonged time period;
3) maintain the same dose utilized in the acute phase;
4) in case of a relapse in the continuation phase, use the same 
principles of non response to treatment.
VII- MAINTENANCE TREATMENT
1) The maintenance treatment is indicated in the following situations: 
a) three or more depressive episodes in the last five years;
b) more than five episodes in lifetime; c) persistent risk of 
relapse.
2) maintain the same dose utilized in the acute phase;
3) The maintenance treatment should be accomplished for at 
least five years and, probably, indefinitely;
4) the recurrence of a depressive episode should be treated using 
the same principles of non response to treatment.
VIII- PRECAUTIONS TO BE ADOPTED WHEN DISCONTINUING 
AN ANTIDEPRESSIVE
1) In order to discontinue an antidepressant, gradually decrease 
the dose during, ate least, four weeks;
2) for patients in maintenance treatment, gradually decrease the 
dose along six months; 
3) in case of a discontinuation reaction, explain and calm down 
the patient. In case of a more intense discontinuation reaction, the 
antidepressant should be reintroduced and discontinued more slowly.
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